STAT3 and β-catenin signaling pathway may affect GSK-3β expression in hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 58, Issue 106, 2011, Pages 487-491

  Wang, Xin Hong ^a   Meng, Xiang Wei ^b   Xing, Hui ^a   Qu, Bo ^a   Han, Ming Zi ^a   Chen, Jing ^a   Fan, Yu Jing ^a   Lu, Cheng Qian ^a   Lu, Zhi Wu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

catenin; Glycogen synthase kinase 3 ; Hepatocellular carcinoma; Signaling pathway; STAT3

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; GLYCOGEN SYNTHASE KINASE 3; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 79958087341     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Brembeck FH, Rosario M, Birchmeier W: Balancing cell adhesion and Wnt signaling, the key role of beta-cat enin. Curr Opin Genet Dev 2006; 16:51-59.
2. Lee HC, Kim M, Wands JR: Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11:1901-1915.
3. Ogasawara N, Tsukamoto T, Mizoshita T, et al: Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer. Histopathology 2006; 49:612-621.
4. Ozaki S, Ikeda S, Ishizaki Y, et al: Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 2005; 14:1437-1443.
5. Martensson A, Oberg A, Jung A, Cederquist K, Stenling R, Palmqvist R: Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncol Rep 2007; 17:447-452.
6. Fuchs SY, Ougolkov AV, Spiegelman VS, et al: Oncogenic beta-catenin signaling networks in colorectal cancer. Cell Cycle 2005; 4:1522-1539.
7. Kawada M, Seno H, Uenoyama Y, et al: Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. Cancer Res 2006; 66:2913-2917.
8. Yan S, Zhou C, Zhang W, et al: beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett 2008; 271:85-97.
9. Hao J, Li TG, Qi X, Zhao DF, Zhao GQ: WNT/beta-catenin pathway up-regulates Stat3 and converges on LIF to prevent differentiation of mouse embryonic stem cells. Dev Biol 2006; 290:81-91.
10. Bongers G, Sallmen T, Passani MB, et al: The Akt/ GSK-3beta axis as a new signaling pathway of the histamine H(3) receptor. J Neurochem 2007; 103:248-258.
11. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB: Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004; 279:39541-39554.
12. Caspi M, Zilberberg A, Eldar-Finkelman H, Rosin-Arbesfeld R: Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. Oncogene 2008; 27:3546-3555.
13. Clifford RL, Deacon K, Knox AJ: Novel Regulation of Vascular Endothelial Growth Factor-A (VEGF-A) by Transforming Growth Factor {beta}1: REQUIREMENT FOR Smads, {beta}-CATENIN, AND GSK3{beta}. J Biol Chem 2008; 283:35337-35353.
14. Liu Y, Borchert GL, Surazynski A, Phang JM: Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene 2008; 27:6729-6737.
15. Lamarre M, Desrosiers RR: Up-regulation of protein L-isoaspartyl methyltransferase expression by lithium is mediated by glycogen synthase kinase-3 inactivation and beta-catenin stabilization. Neuropharmacology 2008; 55:669-676.
16. Holmes T, O'Brien TA, Knight R, et al: Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 2008; 26:1288-1297.
17. Haraguchi K, Ohsugi M, Abe Y, Semba K, Akiyama T, Yamamoto T: Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3beta-mediated phosphorylation of beta-catenin. Oncogene 2008; 27:274-284.
18. Patel S, Woodgett J: Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 2008; 14:351-353.
19. Liza K, Maciej K, Mathew MK, Brent HC: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003; 3:23-32.
20. He S, Zhang D, Cheng F, Gong F, Guo Y: Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep 2009; 1: Epub ahead of print.
21. Wang XH, Meng XW, Sun X, et al: Wnt/β-catenin signaling regulates MAPK and Akt1 expression and growth of hepatocellular carcinoma cells. Neoplasma 2011; 58: 239-244.
22. An WL, Bjorkdahl C, Liu R, Cowburn RF, Winblad B, Pei JJ: Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells. J Neurochem 2005; 92:1104-1115.
23. Moh A, Zhang W, Yu S, Wang J, Xu X, Li J, Fu XY: STAT3 sensitizes insulin signaling by negatively regulating glycogen synthase kinase-3 beta. Diabetes 2008; 57: 1227-1235.
24. Gross ER, Hsu AK, Gross GJ: The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 2006; 291:827-834.